Kaplan-Meierプロットに付加情報を追加するマクロの作成
|
|
|
- おさむ いさし
- 7 years ago
- Views:
Transcription
1 1 / 47 Kaplan-Meier A SAS macro for extended Kaplan-Meier plots 1, 2, Kengo Nagashima 1, Yasunori Sato 2,3 1 Department of Parmaceutical Technochemistry, Josai University 2 School of Medicine, Chiba University 3 Department of Biostatistics, Harvard School of Public Health SAS / &
2 2 / 47 %km_data() Kaplan-Meier Proportion of overall survival MST 95% C.I. 1: high-risk 7.8 [4.4, 9.0) 2: middle-risk 11.3 [6.7,.) 3: low-risk. [8.2,.) No. at risk (1st entry: high, 2nd: middle, 3rd: low) high-risk middle-risk low-risk Months after entry
3 ( ) 1 (Kaplan-Meier ) 2 Log-rank ( ) 3 ( ). Kaplan-Meier.. 3 / 47
4 Kaplan-Meier Kaplan-Meier 1.0 Proportion of overall survival high-risk middle-risk Months after entry, Kaplan-Meier, log-rank P,, 4 / 47
5 (BMJ) No. at risk,, Pocock SJ, et al. BMJ 2008; 336: Fig. 4 5 / 47
6 (JAMA) No. at risk, P Regine WF, et al. JAMA 2008; 299(9): Fig. 2 6 / 47
7 (J Clin Oncol) No. at risk,,, P Reck M, et al. J Clin Oncol 2009; 27(8): Fig. 3 7 / 47
8 (Lancet) No. at risk,,, P Nordlinger B, et al. Lancet 2008; 371(9617): Fig. 2 8 / 47
9 (N Engl J Med) No. at risk, P Karapetis CS, et al. N Engl J Med 2008; 359(17): Fig. 1 9 / 47
10 10 / 47 %km_data()
11 11 / 47 %km_data() 1 Cox 2 3
12 %km_data() 1 LIFETEST Procedure / PHREG Procedure 2 3 GPLOT Procedure /* */ %include "&Path.kmdata_v213.sas"; /* */ %global color1 color2 scolor1 scolor2; %let color1 = cx445694; %let color2 = cxa23a2e; %let scolor1 = cxd4d9e8; %let scolor2 = cxf1cece; /* ( ) */ %km_data( D1, T, GroupC, Censor, 1, out = graph, anno = anno, CI = 1, censext = 1, Size = 2, atrisk = 1, atriskorder = 0 to 12.5 by 2.5, Step = 5, Label = "No. at risk (1st entry: high, 2nd: middle, 3rd: low)", Test = 1, TestX = 98, TestY = 97, Type = logrank, HR = 1, HRX = 98, HRY = 92 ); /* */ proc gplot data = Graph; plot (Sv1 Sv2 Sv3) * T / anno = anno overlay; run; quit; 12 / 47
13 13 / 47 1 data: 2 time: [data] 3 group: [data] 4 censor: [data] 5 censorv: [censor] 6 out: 7 anno: annotate ( annotate ) HP, 7
14 14 / Proportion of overall survival No. at risk (1st entry: high, 2nd: middle) high-risk middle-risk Months after entry
15 15 / 47 data D2; set D1; where Group in (1, 2); %km_data( D2, T, GroupC, Censor, 1, out = graph, anno = anno, censext = 1, cwidth = 20, Size = 1, Step = 5, afont = " Arial ", atrisk = 1, atriskorder = 0 to 12.5 by 2.5, Base = 0, Label = "No. at risk (1st entry: high, 2nd: middle)" ); atrisk = 1 atriskorder Base Label
16 16 / Log-rank P = Proportion of overall survival high-risk middle-risk Months after entry
17 17 / 47 data D2; set D1; where Group in (1, 2); %km_data( D2, T, GroupC, Censor, 1, out = graph, anno = anno, censext = 1, cwidth = 20, Size = 1, Step = 5, afont = " Arial ", Test = 1, TestX = 98, TestY = 97, Type = logrank ); Test = 1 TestX, TestY Type
18 18 / 47 Cox 1.0 2:middle-risk HR = [0.360, 1.040] Proportion of overall survival high-risk middle-risk Months after entry
19 19 / 47 Cox data D2; set D1; where Group in (1, 2); %km_data( D2, T, GroupC, Censor, 1, out = graph, anno = anno, censext = 1, cwidth = 20, Size = 1, Step = 5, afont = " Arial ", HR = 1, HRX = 98, HRY = 97 ); HR = 1 HRX, HRY
20 20 / 47 Proportion of overall survival : high-risk 2: middle-risk MST 95% C.I. 7.8 [4.4, 9.0) 11.3 [6.7,.) 0.0 high-risk middle-risk Months after entry
21 21 / 47 data D2; set D1; where Group in (1, 2); %km_data( D2, T, GroupC, Censor, 1, out = graph, anno = anno, censext = 1, cwidth = 20, Size = 1, Step = 5, afont = " Arial ", MST = 1, MlabX = 60, MmedX = 83, MciX = 98, MSTY = 95 ); MST = 1 MlabX, MmedX, MciX, MSTY
22 22 / 47 (1) 1.0 Proportion of overall survival high-risk middle-risk Months after entry
23 23 / 47 (1) data D2; set D1; where Group in (1, 2); %km_data( D2, T, GroupC, Censor, 1, out = graph, anno = anno, censext = 1, cwidth = 20, Size = 1, Step = 5, afont = " Arial " );, CI = 1
24 24 / 47 (2) 1.0 Proportion of overall survival high-risk middle-risk Months after entry
25 (2) data D2; set D1; where Group in (1, 2); %km_data( D2, T, GroupC, Censor, 1, out = graph, anno = anno, censext = 1, cwidth = 20, Size = 1, Step = 5, afont = " Arial " ); data Graph2; length vname $10.; set Graph; var=sv1; vname= Sv1 ; output; var=sv2; vname= Sv2 ; output; var=sl1; vname= zsl1 ; output; var=sl2; vname= zsl2 ; output; var=su1; vname= zsu1 ; output; var=su2; vname= zsu2 ; output; proc sort data = Graph2; by vname T; proc gplot data = Graph2; plot var * T = vname / legend = legend1; legend1 label = none position = (inside) mode = share across = 1 origin = (1, 0.2) value = (h = 1 "high-risk" "middle -risk") order = ("Sv1" "Sv2"); symbol1 i = steplj c="&color1." w=20; symbol2 i = steplj c="&color2." w=20; symbol3 i = steplj c="&scolor1." w=20 l=2; symbol4 i = steplj c="&scolor2." w=20 l=2; symbol5 i = steplj c="&scolor1." w=20 l=2; symbol6 i = steplj c="&scolor2." w=20 l=2; run; quit;, GPLOT Procedure Sv1, Sv2 (order ) 25 / 47
26 26 / 47 %km_data() %km_data( D2, T, GroupC, Censor, 1, out = graph, anno = anno, censext = 1, cwidth = 20 ); GPLOT Procedure, ( emf, eps )
27 27 / 47 ODS Graph LIFETEST Procedure ODS Graph SAS 9.2 ods listing gpath = "&Path." style = Statistical sge = on; ods graphics on / antialias = on border = off scale = on imagename = "Lifetest_ods" width = in height = 4 in; proc lifetest data = D1 plots=(survival(atrisk=(0 to 12.5 by 2.5) test cl)); time T * Censor(1); strata GroupC; run; ods graphics off; ods listing close; ods listing; emf, eps
28 28 / 47 ODS Graph?
29 29 / 47 ODS Graph 1 ODS Graphics Editor 2 TEMPLATE Procedure
30 30 / 47 ODS Graphics Editor sge ( : ods listing sge = on;)
31 31 / 47 ODS Graphics Editor 1... TEMPLATE Procedure
32 32 / 47 TEMPLATE Procedure SAS ( )
33 33 / 47 ODS STYLE Statement style.statistical proc template; define style Styles.MyStatistical; parent = styles.statistical; style GraphFonts / GraphTitleFont =("Times New Roman",24pt, bold) GraphFootnoteFont =("Times New Roman",24pt, italic) GraphLabelFont =("Times New Roman",24pt) GraphValueFont =("Times New Roman", 24pt) GraphDataFont =("Times New Roman", 24pt) GraphUnicodeFont =(" <MTsans -serif-unicode> ", 24pt) GraphAnnoFont =("Times New Roman", 24pt); end; run; style proc template; path sashelp.tmplmst; list styles; run;
34 34 / 47 proc template; source Stat.Lifetest.Graphics.ProductLimitSurvival; run;, Template, Stat.Lifetest.Graphics.ProductLimitSurvival
35 35 / 47 ( ) (134 )
36 36 / 47 ENTRYTITLE Statement entrytitle "Product -Limit Survival Estimates"; if (EXISTS(SECONDTITLE)) entrytitle SECONDTITLE / textattrs=graphvaluetext; endif;
37 37 / 47 SCATTERPLOT Statement MARKERATTRS Option if (PLOTCENSORED) scatterplot y=censored x=time / group=stratum index=stratumnum markerattrs=(symbol=plus); endif; MARKERATTRS Option symbol size if (PLOTCENSORED) scatterplot y=censored x=time / group=stratum index=stratumnum markerattrs=(symbol=circlefilled size=8pt); endif;
38 38 / 47 DISCRETELEGEND Statement TYTLE Option, LOCATION Option, HALIGN Option, VALIGN Option, BORDER Option DiscreteLegend "Survival" / title=groupname location=outside; TYTLE, LOCATION, HALIGN VALIGN, BORDER DiscreteLegend "Survival" / location=inside HALIGN=LEFT VALIGN=BOTTOM border=false; TEMPLATE Procedure proc template;... run;
39 39 / 47 TEMPLATE Procedure
40 1.0 Log-rank P = Proportion of overall survival No. at risk (1st entry: high, 2nd: middle) high-risk Months after entry middle-risk TEMPLATE Procedure ( 600 ), ; %km_data() GPLOT Procedure,, / 47
41 41 / 47 %km_data() ODS Graph / TEMPLATE Procedure
42 42 / 47 Example 1 Proportion of overall survival Log-rank P = :middle-risk HR = [0.359, 1.038] 3:low-risk HR = [0.289, 0.871] No. at risk (1st entry: high, 2nd: middle, 3rd: low) high-risk middle-risk low-risk Months after entry
43 43 / 47 Example 2 Proportion of overall survival Log(LR) P = :middle-risk HR = [0.359, 1.038] 3:low-risk HR = [0.289, 0.871] high-risk middle-risk low-risk Months after entry
44 44 / 47 Example 3 Proportion of overall survival MST 95% C.I. 1: high-risk 7.8 [4.4, 9.0) 2: middle-risk 11.3 [6.7,.) 3: low-risk. [8.2,.) No. at risk (1st entry: high, 2nd: middle, 3rd: low) high-risk middle-risk low-risk Months after entry
45 45 / 47 Example Wilcoxon P = Proportion of overall survival No. at risk (1st entry: high, 2nd: middle, 3rd: low) high-risk middle-risk low-risk Months after entry
46 46 / 47 Example Log-rank P = Proportion of overall survival No. at risk (1st entry: high, 2nd: middle) high-risk middle-risk Months after entry
47 47 / 47 [1] SAS Institute Inc. SAS 9.2 Macro Language: Reference. Cary, NC, USA: SAS Institute Inc., [2] SAS Institute Inc. SAS/STAT(R) 9.2 User s Guide, Second Edition. Cary, NC, USA: SAS Institute Inc., [3] SAS Institute Inc. SAS/GRAPH(R) 9.2: Graph Template Language User s Guide, Second Edition. Cary, NC, USA: SAS Institute Inc., [4] Pocock SJ, Travison TG, Wruck LM. How to interpret figures in reports of clinical trials. BMJ 2008; 336(7654): [5] Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs Gemcitabine chemotherapy before and after Fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299(9): [6] Reck M, Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27(8): [7] Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371(9617): [8] Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from Cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359(17):
Kaplan-Meierプロットに付加情報を追加するマクロの作成
Kaplan-Meier 1, 2,3 1 2 3 A SAS macro for extended Kaplan-Meier plots Kengo Nagashima 1, Yasunori Sato 2,3 1 Department of Parmaceutical Technochemistry, Josai University 2 School of Medicine, Chiba University
Microsoft PowerPoint - 【魚住】 発表原稿【Web公開用】.ppt [互換モード]
SG (Statistical Graphics) Procedures による Kaplan-Meier プロットの作成 魚住龍史 1, * 浜田知久馬 2 1 日本化薬株式会社医薬データセンター 2 東京理科大学工学部経営工学科 Kaplan-Meier plots using Statistical Graphics Procedures Ryuji Uozumi 1, * and Chikuma
untitled
SGPLOT 1, 2 * 1 1 2 Drawing the useful graphs for the tumor shrinkage assessment in cancer clinical trials Innovative uses of new features in PROC SGPLOT Ryuji Uozumi 1, 2 * and Chikuma Hamada 1 1 Department
スライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
Presentation Title Goes Here
SAS 9: (reprise) SAS Institute Japan Copyright 2004, SAS Institute Inc. All rights reserved. Greetings, SAS 9 SAS 9.1.3 Copyright 2004, SAS Institute Inc. All rights reserved. 2 Informations of SAS 9 SAS
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
SAS Enterprise Guideによるデータ解析入門
........ 1 / 70.... SAS Enterprise Guide Kengo NAGASHIMA Laboratory of Biostatistics, Department of Parmaceutical Technochemistry, Josai University 2010 11 16 ........ 2 / 70 (SAS / SAS Enterprise Guide
*1 * Wilcoxon 2 2 t t t t d t M t N t M t n t N t n t N t d t N t t at ri
Wilcoxon H23 BioS 1 Wilcoxon 2 2.1 1 2 1 0 1 1 5 0 1 2 7 0 1 3 8 1 1 4 12 0 2 5 2 0 2 6 3 1 2 7 4 1 2 8 10 0 Wilcoxon 2.2 S 1 t S 2 t Wilcoxon H 0 H 1 H 0 : S 1 t S 2 t H 1 : S 1 t S 2 t 1 *1 *2 2.3 2.3.1
7 / 70 8 / 70 SAS Enterprise Guide, Windows SAS, SAS,,,, SAS SAS Enterprise Guide SAS: SAS Enterprise Guide:, SAS SAS Enterprise Guide... 5 / 70 6 / 7
3 / 70 4 / 70 SAS Enterprise Guide (SAS / SAS Enterprise Guide ) Kengo NAGASHIMA Laboratory of Biostatistics, Department of Parmaceutical Technochemistry, Josai University 2010 11 16 1 / 70 2 / 70 SAS
SAS Enterprise Guideによるデータ解析入門
1 / 83.. SAS Enterprise Guide.... Kengo NAGASHIMA Laboratory of Biostatistics, Department of Parmaceutical Technochemistry, Josai University 2011 11 15 2 / 83 (SAS / SAS Enterprise Guide ) SAS SAS (Statistical
ODS GRAPHICS ON; ODS GRAPHICS ON; PROC TTEST DATA=SASHELP.CLASS SIDE=2 DIST=NORMAL H0=58 PLOTS(ONLY SHOWH0)=(SUMMARY); VAR HEIGHT;
Summer 2009 1 8 12 14 16 16 16 ODS GRAPHICS ON; ODS GRAPHICS ON; PROC TTEST DATA=SASHELP.CLASS SIDE=2 DIST=NORMAL H0=58 PLOTS(ONLY SHOWH0)=(SUMMARY); VAR HEIGHT; PROC SGPLOT DATA=SASHELP.PRDSALE; HBAR
Slide 1
ODS 統 計 グラフ 機 能 を 用 いたグラフの 作 成 SAS Institute Japan 株 式 会 社 プロフェッショナルサービス 本 部 テクニカルサポート 部 深 澤 武 志 Copyright 2010 SAS Institute Inc. All rights reserved. 目 次 ODSとは ODS 統 計 グラフのご 紹 介 ODSテンプレートに 関 して ODS 統
JMP V4 による生存時間分析
V4 1 SAS 2000.11.18 4 ( ) (Survival Time) 1 (Event) Start of Study Start of Observation Died Died Died Lost End Time Censor Died Died Censor Died Time Start of Study End Start of Observation Censor
スライド 1
ベクター形式を用いたグラフの作成と有用性 平井隆幸 1) 吉田早織 1) 叶健 1) 魚住龍史 2) 1) 日本化薬株式会社開発戦略部 2) 京都大学大学院医学研究科 Graphical representation using vector graphics format Takayuki Hirai 1), Saori Yoshida 1), Takeshi Kanou 1), Ryuji Uozumi
20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of
Autumn 2007 1 5 8 12 14 14 15 %!SASROOT/sassetup SAS Installation Setup Welcome to SAS Setup, the program used to install and maintain your SAS software. SAS Setup guides you through a series of menus
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
ProVisionaire Control V3.0セットアップガイド
ProVisionaire Control V3 1 Manual Development Group 2018 Yamaha Corporation JA 2 3 4 5 NOTE 6 7 8 9 q w e r t r t y u y q w u e 10 3. NOTE 1. 2. 11 4. NOTE 5. Tips 12 2. 1. 13 3. 4. Tips 14 5. 1. 2. 3.
ERBITUX_WEBセミナー表紙台_2015.ai
2014520 1st-lineEGFR EGFR Web2014520 URL http://www.erbitux-crc-seminar.jp/ Overview 4 VEGFEGFR FIRE-3 201414 EGFR2009 2nd-line5-FU CPT-11 CPT-11 2010 1st-line2nd-lineKRAS 1st-lineEGFR 2014 1st-lineKRAS
PHREG プロシジャにおける 共変量調整解析に関連したオプション機能 魚住龍史 1 * 矢田真城 2 浜田知久馬 3 1 京都大学大学院医学研究科医学統計生物情報学 2 エイツーヘルスケア株式会社 3 東京理科大学 Investigating fascinating aspects associa
PHREG プロシジャにおける 共変量調整解析に関連したオプション機能 魚住龍史 1 * 矢田真城 2 浜田知久馬 3 1 京都大学大学院医学研究科医学統計生物情報学 2 エイツーヘルスケア株式会社 3 東京理科大学 Investigating fascinating aspects associated with covariate-adjusted analysis using PHREG procedure
Dim obwsmgr As New SASWorkspaceManager. WorkspaceManager Dim errstring As String Set obws = obwsmgr.workspaces.createworkspacebyserver( _ "My workspace", VisibilityProcess, Nothing, _ "", "", errstring)
日本消化器外科学会雑誌第29巻第9号
Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe
5 11 3 1....1 2. 5...4 (1)...5...6...7...17...22 (2)...70...71...72...77...82 (3)...85...86...87...92...97 (4)...101...102...103...112...117 (5)...121...122...123...125...128 1. 10 Web Web WG 5 4 5 ²
Autumn 2005 1 9 13 14 16 16 DATA _null_; SET sashelp.class END=eof; FILE 'C: MyFiles class.txt'; /* */ PUT name sex age; IF eof THEN DO; FILE LOG; /* */ PUT '*** ' _n_ ' ***'; END; DATA _null_;
Microsoft PowerPoint - 【配布・WEB公開用】SAS発表資料.pptx
生存関数における信頼区間算出法の比較 佐藤聖士, 浜田知久馬東京理科大学工学研究科 Comparison of confidence intervals for survival rate Masashi Sato, Chikuma Hamada Graduate school of Engineering, Tokyo University of Science 要旨 : 生存割合の信頼区間算出の際に用いられる各変換関数の性能について被覆確率を評価指標として比較した.
R Commanderを用いたデータ解析
1 / 82 R Commander Kengo NAGASHIMA Laboratory of Biostatistics, Department of Parmaceutical Technochemistry, Josai University 2010 1 5 R R Commander 2 / 82 R, "The Comprehensive R Archive Network (CRAN)",
untitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- [email protected] http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
DATA Sample1 /**/ INPUT Price /* */ DATALINES
3180, 3599, 3280, 2980, 3500, 3099, 3200, 2980, 3380, 3780, 3199, 2979, 3680, 2780, 2950, 3180, 3200, 3100, 3780, 3200 DATA Sample1 /**/ INPUT Price @@ /* @@1 */ DATALINES 3180 3599 3280 2980 3500 3099
日本消化器外科学会雑誌第30巻第3号
Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment
E3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL
E3200 BV FOLFOX4 FOLFOX4 PFS 4.5 7.5 0.518 95% 0.42, 0.65 p
untitled
January 2009 Rotor-Gene Q Sample & Assay Technologies 1 1-1 1.1 1-1 1.2 Rotor-Gene Q 1-1 1.3 Rotor-Gene Q 1-1 1.4 1-1 2 2-1 2.1 Run File 2-1 2.2 2-2 2.3 2-2 2.4 PCR 2-3 2.5 2-3 2.6 2-4 2.7 2-4 2.8 2-5
2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
VOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
ON A FEW INFLUENCES OF THE DENTAL CARIES IN THE ELEMENTARY SCHOOL PUPIL BY Teruko KASAKURA, Naonobu IWAI, Sachio TAKADA Department of Hygiene, Nippon Dental College (Director: Prof. T. Niwa) The relationship
1 2 3
INFORMATION FOR THE USER DRILL SELECTION CHART CARBIDE DRILLS NEXUS DRILLS DIAMOND DRILLS VP-GOLD DRILLS TDXL DRILLS EX-GOLD DRILLS V-GOLD DRILLS STEEL FRAME DRILLS HARD DRILLS V-SELECT DRILLS SPECIAL
EBM Reviews Ovid Ovid EBM Reviews ACP Journal Club Cochrane Database of Systematic Revie
EBM Reviews 2006 4 Ovid http://www.usaco.co.jp/products/ovid/ovidplatform.html Ovid EBM Reviews ACP Journal Club Cochrane Database of Systematic Reviews CDSR Database of Abstracts of Reviews of Effectiveness
6 Tgif William Chia-Wei Chang tgif 3.0 pixmap URL Tgif 6.1: Tgif
6 Tgif 121 6.1 Tgif............................ 122 6.2..................... 123 6.2.1...................... 126 6.2.2 Dash, Type, Style, Width.......... 127 6.2.3 Pen, Fill............. 128 6.2.4 Text......................
日本製薬工業協会シンポジウム 生存時間解析の評価指標に関する最近の展開ー RMST (restricted mean survival time) を理解するー 2. RMST の定義と統計的推測 2018 年 6 月 13 日医薬品評価委員会データサイエンス部会タスクフォース 4 生存時間解析チー
日本製薬工業協会シンポジウム 生存時間解析の評価指標に関する最近の展開ー RMST (restricted mean survival time) を理解するー 2. RMST の定義と統計的推測 2018 年 6 月 13 日医薬品評価委員会データサイエンス部会タスクフォース 4 生存時間解析チーム 日本新薬 ( 株 ) 田中慎一 留意点 本発表は, 先日公開された 生存時間型応答の評価指標 -RMST(restricted
ベバシズマブ併用 FOLFOX/FOLFIRI療法
第 5 回福岡大学病院と院外薬局とのがん治療連携勉強会 ベバシズマブ併用 FOLFOX/FOLFIRI 療法 福岡大学病院腫瘍 血液 感染症内科 田中俊裕 本日の講演内容 大腸がんの治療方法について概説 アバスチン併用 FOLFOX/FOLFIRI 療法の治 療成績について 2005 年にがんで死亡した人は 325,941 例 ( 男性 196,603 例 女性 129,338 例 ) 2 位 4
1.eps
PROC SORT DATA=SortData OUT=OutData NOEQUALS; BY DESCENDING group; /* group*/ /* */ DATA MeansData1; INPUT x y; DATALINES; 2 5 4 6 1 9 3 12 ; /* MEANS */ PROC MEANS DATA=MeansData1 MEAN MEDIAN SUM; VAR
5 1 2 3 4 5 6 7 8 9 10 11 12 1 132 CMOS Setup Utility - Copyright (C) 1984-2000 Award Software Power Management Setup ACPI Suspend Type S3 (STR) Power Management User Define Video Off Method DPMS Video
course pptx
ParaView () 20105141CAE OPENFOAM (R) is a registered trade mark of OpenCFD Limited, the producer of the OpenFOAM software and owner of the OPENFOAM (R) and OpenCFD (R) trade marks. This offering is not
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
スライド 1
ODS POWERPOINTの 活 用 : SASからMicrosoft PowerPointへの エクスポート 吉 田 早 織 1) 平 井 隆 幸 1) 叶 健 1) 魚 住 龍 史 2) 1) 日 本 化 薬 株 式 会 社 開 発 戦 略 部 2) 京 都 大 学 大 学 院 医 学 研 究 科 Application of ODS POWERPOINT s advanced features
1 I EViews View Proc Freeze
EViews 2017 9 6 1 I EViews 4 1 5 2 10 3 13 4 16 4.1 View.......................................... 17 4.2 Proc.......................................... 22 4.3 Freeze & Name....................................
スライド 1
ODS GRAPHICS を用いた臨床試験データの可視化への挑戦 豊泉樹一郎, 財前政美, 北西由武, 都地昭夫塩野義製薬株式会社解析センター Challenge to Visualize the Clinical Trial Data with ODS Graphics Kiichiro Toyoizumi 1) Masami Zaizen 1) Yoshitake Kitanishi 1) Akio
スライド 1
日本肺がん学会 肺がん診療ガイドライン 病理病期 I II IIIA 期 術後補助化学療法 1 術後補助療法 Pubmed を用いて以下を検索 : Key words:lung cancer, adjuvant therapy, non small cell lung cancer Limitation: 期間 :2004/12/01-2011/08/31 言語 ;English 文献 ;Clinical
VOL. 34 S-2 CHEMOTH8RAPY 913
VOL. 34 S-2 CHEMOTH8RAPY 913 914 CHEMOTHERAPY APR. 1986 Fig. 1 Chemical structure of T-2588 and T-2525 T- 2588 pivaloyloxymethyl (+ )- (6 R, 7 R)-7-[(Z)-2- (2-amino- 4-thiazolyl)-2-methox yiminoacetamido]-3-[(
_02.indd
30, 11-16, 2010 Z Z score Computed tomography ROC analysis 3 CT 1,2 CT 1/3 3 5 CT CT 6 7,8 MCA ASPECTS Alberta Stroke Programme Early CT Score 4 10 CT ASPECTS 50% 9 Z 10 CT Z CT 10 Z Z Z receiver operating
Release Notes for JMP book
8.0.2 JMP, A Business Unit of SAS SAS Campus Drive Cary, NC 27513 SAS Institute Inc. 2009.JMP 8.0.2, Cary, NC: SAS Institute Inc. JMP 8.0.2 Copyright 2009, SAS Institute Inc., Cary, NC, USA All rights
こんにちは由美子です
Sample size power calculation Sample Size Estimation AZTPIAIDS AIDSAZT AIDSPI AIDSRNA AZTPr (S A ) = π A, PIPr (S B ) = π B AIDS (sampling)(inference) π A, π B π A - π B = 0.20 PI 20 20AZT, PI 10 6 8 HIV-RNA
Gynecologic Oncology Trial and Investigation Consortium GOTIC-002
Gynecologic Oncology Trial and Investigation Consortium GOTIC-002 3 8 ...2...2...2...2...3...4...4...5...9...9...9...9...9... 13... 13... 13... 13... 13... 13... 13... 14... 14... 15... 15... 15...
要旨 : データステップ及び SGPLOT プロシジャにおける POLYGON/TEXT ステートメントを利用した SAS プログラムステップフローチャートを生成する SAS プログラムを紹介する キーワード :SGPLOT, フローチャート, 可視化 2
SAS プログラムの可視化 - SAS プログラムステップフローチャート生成プログラムの紹介 - 福田裕章 1 ( 1 MSD 株式会社 ) Visualization of SAS programs Hiroaki Fukuda MSD K.K. 要旨 : データステップ及び SGPLOT プロシジャにおける POLYGON/TEXT ステートメントを利用した SAS プログラムステップフローチャートを生成する
52-2.indb
Jpn. J. Health Phys., 52 (2) 55 60 (2017) DOI: 10.5453/jhps.52.55 * 1 * 2 * 2 * 3 * 3 2016 10 28 2017 3 8 Enhancement of Knowledge on Radiation Risk Yukihiko KASAI,* 1 Hiromi KUDO,* 2 Masahiro HOSODA,*
Release Notes.book
8.0.1 JMP, A Business Unit of SAS SAS Campus Drive Cary, NC 27513 SAS Institute Inc. 2009.JMP 8.0.1 Release Notes, Cary, NC: SAS Institute Inc. JMP 8.0.1 Copyright 2009, SAS Institute Inc., Cary, NC, USA
: (EQS) /EQUATIONS V1 = 30*V F1 + E1; V2 = 25*V *F1 + E2; V3 = 16*V *F1 + E3; V4 = 10*V F2 + E4; V5 = 19*V99
218 6 219 6.11: (EQS) /EQUATIONS V1 = 30*V999 + 1F1 + E1; V2 = 25*V999 +.54*F1 + E2; V3 = 16*V999 + 1.46*F1 + E3; V4 = 10*V999 + 1F2 + E4; V5 = 19*V999 + 1.29*F2 + E5; V6 = 17*V999 + 2.22*F2 + E6; CALIS.
TM-m30 詳細取扱説明書
M00094106 Rev. G Seiko Epson Corporation 2015-2018. All rights reserved. 2 3 4 5 6 7 8 Bluetooth 9 ... 71 10 1 11 Bluetooth 12 1 13 1 2 6 5 4 3 7 14 1 1 2 3 4 5 15 16 ONF 1 N O O N O N N N O F N N F N
RT300i/RT140x/RT105i 取扱説明書
2 3 4 5 6 7 8 9 10 Bold face Enter Ctrl Tab BS Del Typewriter face RT105i RT300i RT140p RT140f RT140i RT140e RT105i RT300i 11 RARP 9600 bit/s 8 http://www.rtpro.yamaha.co.jp/ ftp.rtpro.yamaha.co.jp 12
Microsoft Word - Meta70_Preferences.doc
Image Windows Preferences Edit, Preferences MetaMorph, MetaVue Image Windows Preferences Edit, Preferences Image Windows Preferences 1. Windows Image Placement: Acquire Overlay at Top Left Corner: 1 Acquire
TM-m30 詳細取扱説明書
M00094101 Rev. B Seiko Epson Corporation 2015-2016. All rights reserved. 2 3 4 5 6 7 8 Bluetooth 9 Bluetooth 10 1 11 Bluetooth 12 1 13 1 2 6 5 4 3 7 14 1 1 2 3 4 5 15 16 ONF 1 N O O N O N N N O F N N F
胃癌診療 -内視鏡治療と予防の最前線-
K net 21 5 28 10-20 5 100 32 K net 19 1 18 - - K net 21 5 28 2 2 RCT LECS NOTES 19 2 Narrow Band Imaging Light Penetration Depth Light penetration depth within the tissue highly depends on the wavelength.
RT300/140/105シリーズ 取扱説明書
REMOTE & BROADBAND ROUTER RT300i/RT140p/RT140f/RT140i RT140e/RT105p/RT105i/RT105e 2 3 4 5 6 7 8 9 10 Bold face Enter Ctrl Tab BS Del Console RT105i RT300i RT140p RT140f RT140i RT140e RT105p RT105i RT105e
スケーリング理論とはなにか? - --尺度を変えて見えること--
? URL: http://maildbs.c.u-tokyo.ac.jp/ fukushima mailto:[email protected] DEX-SMI @ 2006 12 17 ( ) What is scaling theory? DEX-SMI 1 / 40 Outline Outline 1 2 3 4 ( ) What is scaling theory?
TM-T88VI 詳細取扱説明書
M00109801 Rev. B 2 3 4 5 6 7 8 9 10 Bluetooth 11 12 Bluetooth 13 14 1 15 16 Bluetooth Bluetooth 1 17 1 2 3 4 10 9 8 7 12 5 6 11 18 1 19 1 3 4 2 5 6 7 20 1 21 22 1 23 24 1 25 SimpleAP Start SSID : EPSON_Printer
PROC OPTIONS; NOTE: XXXXXXXXSASV8.2 SASV9.1 SASV9.1 LIBNAME source ""; LIBNAME target V9 ""; PROC MIGRATE IN=source OUT=target ; RUN ; LIBNAME v8lib V8 "d: saslib v8lib"; LIBNAME v9lib V9 "d: saslib
3 4 2
A Comparison of SAS Functions Designed for Creating Excel Output in a Stand-alone Environment and a BI Environment. Koichi Satoh Takumi Information Technology Co., Ltd. ODS EXCELXP ODS HTML ODS CSVALL
第3回委員会(2月20日)資料NO
ISO9001 ISO9001 E.Codman A.Donabedian Benefit, utility and risk A.Donabedian risk Output Output Output Adequacy Continuity / over time Efficacy (randomized controlled clinical trials) 7 Effectiveness
SAS Web XML * ** * ** Web Data Analysis with SAS Input and Output of XML Data and Application to Real Estate Valuation Map Junnosuke Matsushima*, Hiro
SAS Web XML * ** * ** Web Data Analysis with SAS Input and Output of XML Data and Application to Real Estate Valuation Map Junnosuke Matsushima*, Hiroshi Ishijima**, Ikue Watanabe *Clinical Research Planning
1_2.eps
第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075
8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
